Immune responses to varicella-zoster virus (Q41150938)

27 September 2017

1 reference

title

Immune responses to varicella-zoster virus (English)

1 reference

27 September 2017

Arvin AM

1

1 reference

27 September 2017

1 September 1996

1 reference

Infectious Disease Clinics of North America

27 September 2017

1 reference

27 September 2017

10

1 reference

27 September 2017

3

1 reference

27 September 2017

529-570

1 reference

Cell-Mediated Immunity to Varicella-Zoster Virus

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunologic Evidence of Reinfection with Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Human Leukocyte Interferon for the Treatment of Varicella in Children with Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cellular and Humoral Immunity in the Pathogenesis of Recurrent Herpes Viral Infections in Patients with Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Human T Cells Recognize Multiple Epitopes of an Immediate Early/Tegument Protein (IE62) and Glycoprotein I of Varicella Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody Response to Varicella-Zoster Virus after Natural or Vaccine-Induced Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Mucosal cell-mediated immunity to varicella zoster virus: role in protection against disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Administration of live varicella vaccine to children wtih leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Detection of varicella-zoster virus DNA in nasopharyngeal secretions of immune household contacts of varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-zoster virus-specific HLA-restricted cytotoxicity of normal immune adult lymphocytes after in vitro stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Evolution of recurrent herpes simplex lesions. An immunohistologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-zoster virus. The Fourteenth Fleming lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Peripheral Blood Mononuclear Cells of the Elderly Contain Varicella-Zoster Virus DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Western blot analysis of antibody to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Human monoclonal antibodies neutralizing varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody to Early Antigens of Varicella-Zoster Virus during Varicella and Zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella Vaccine: The American Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Clinical Reinfection with Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Live attenuated varicella vaccine. Efficacy for children with leukemia in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunization of healthy adults with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunoprecipitable polypeptides specified by varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunology of the varicella-zoster virus glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Herpes zoster in an adult recipient of live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody responses in recipients of varicella vaccine assayed by immunoblotting

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cell-mediated immunity to varicella zoster virus in children being treated for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Lymphocyte responses to varicella zoster virus in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-zoster virus-specific immunity after herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Human serum antibodies to varicella-zoster virus thymidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Diagnostic Skin Test Reactions with Varicella Virus Antigen and Clinical Application of the Test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Development and Characteristics of the Cellular Immune Response to Infection with Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody response to varicella-zoster virus surface glycoproteins in chickenpox and shingles

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Determination of immunity to varicella-zoster virus by means of an intradermal skin test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immune response of elderly individuals to a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Detection of Varicella-Zoster Virus-Specific IgA Antibodies in Varicella and Zoster Patients and in Healthy Adults of Various Ages by Solid-Phase Radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Serum Antibody Levels as Risk Factors in the Dissemination of Herpes Zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Human Leukocyte Interferon for the Treatment of Herpes Zoster in Patients with Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cell-Mediated Immunity to Varicella-Zoster Virus after Allogeneic Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Investigation of Varicella-Zoster Virus-infected Cell Proteins that Elicit Antibody Production during Primary Varicella Using the Immune Transfer Method

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cell-mediated immunity to varicella-zoster virus infection in subjects with lymphoma or leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Antibody assays suitable for assessing immune responses to live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Specific IgM antibody in serum of patients with herpes zoster infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Sensitivity of different assay systems for immunoglobulin M responses to varicella-zoster virus in reactivated infections (zoster).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Class-specific antibody responses to early and late antigens of varicella and herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Kinetics and Viral Protein Specificity of the Cytotoxic T Lymphocyte Response in Healthy Adults Immunized with Live Attenuated Varicella Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Biologic and Immunologic Characterization of the Soluble Skin-Test Antigen of Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cellular Events in Zoster Vesicles: Relation to Clinical Course and Immune Parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

A human monoclonal antibody against varicella-zoster virus glycoprotein III

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Live vaccine used to prevent the spread of varicella in children in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Varicella-zoster virus (VZV) reactivation is related to the low response of VZV-specific immunity after chickenpox in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Molecular Dissection of the Humoral Immune Response to Individual Varicella-Zoster Viral Proteins During Chickenpox, Quiescence, Reinfection, and Reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Subclinical Varicella-Zoster Virus Viremia, Herpes Zoster, and T Lymphocyte Immunity to Varicella-Zoster Viral Antigens after Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Evaluation of Varicella-Zoster Immune Globulin: Protection of Immunosuppressed Children after Household Exposure to Varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Attenuated varicella virus vaccine in children with renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

Immune response after exposure to varicella zoster virus: characterization of virus-specific antibodies and their corresponding antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970312-3

7 January 2021

10.1016/S0891-5520(05)70312-3

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8856351